HIV patients may ditch daily pills for Twice-Yearly antibody shots

NCT ID NCT05275998

Completed Disease control Sponsor: TaiMed Biologics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two lab-made antibodies, TMB-365 and TMB-380, in 51 adults with HIV whose virus was already controlled by daily oral medication. The goal was to see if switching to these antibody infusions every 8 weeks could keep the virus suppressed safely. Results will show whether this approach could offer a long-acting alternative to daily pills, but it is not a cure—patients would still need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

CAN Community Health

Fort Lauderdale, Florida, 33316, United States
Crofoot Research Center, Inc.

Houston, Texas, 77098, United States
Midway Immunology and Research Center

Ft. Pierce, Florida, 34892, United States
North Texas Infectious Disease Consultants

Dallas, Texas, 75246, United States
Orlando Immunology Center

Orlando, Florida, 32803, United States
Quest Clinical Research

San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.